Natco Pharma Downgraded to Sell Amid Weak Financials and Bearish Technicals

Quality Assessment: Declining Financial Health Raises Concerns

Natco Pharma’s recent quarterly results have been disappointing, with the company reporting very negative financial performance in Q4 FY25-26. Net sales for the quarter stood at ₹739.10 crores, marking a sharp decline of 35.2% compared to the previous four-quarter average. Profit before tax excluding other income (PBT less OI) plunged by 83.1% to ₹66.30 crores, while net profit after tax (PAT) fell by 31.2% to ₹267.90 crores. This marks the second consecutive quarter of negative results, underscoring a troubling trend in operational performance.

Over the last five years, the company’s net sales have grown at a modest annual rate of 14.72%, which is below expectations for a growth-oriented pharmaceutical firm. Earnings per share (EPS) have also contracted significantly, with a 31.18% fall reported recently. These figures highlight a weakening earnings trajectory and raise questions about the company’s ability to sustain long-term growth.

Despite these setbacks, Natco Pharma maintains a high return on equity (ROE) of 16.51%, reflecting efficient management and capital utilisation. The company is also net-debt free, which provides some financial stability and flexibility in a volatile market environment.

Valuation: Attractive Yet Not Enough to Offset Risks

From a valuation standpoint, Natco Pharma presents a mixed picture. The stock trades at a price-to-book (P/B) ratio of 1.8, which is considered attractive relative to its peers and historical averages. This valuation suggests that the market is pricing in some of the company’s challenges, potentially offering a margin of safety for value investors.

However, the stock’s recent price performance has been lacklustre. It closed at ₹917.30 on 5 August 2026, down 1.24% from the previous close of ₹928.80. Over the past year, the stock has generated a negative return of 1.92%, underperforming the broader BSE500 index and the Sensex, which posted a 3.20% and 7.97% decline respectively over the same period. Longer-term returns also lag behind benchmarks, with a five-year return of -9.59% compared to the Sensex’s robust 44.25% gain.

Institutional investors hold a significant 22.61% stake in Natco Pharma, indicating confidence from sophisticated market participants who typically conduct thorough fundamental analysis. Yet, the stock’s valuation appeal is currently overshadowed by deteriorating earnings and weak price momentum.

Financial Trend: Negative Momentum Persists

Natco Pharma’s financial trend has deteriorated markedly in recent quarters. The company’s net sales and profits have both contracted sharply, with a 35.2% fall in quarterly sales and a 31.2% decline in PAT signalling operational challenges. The downward trend is further emphasised by the company’s negative returns over the past year and underperformance relative to the Sensex and BSE500 indices.

While the company’s five-year sales growth rate of 14.72% is moderate, the recent quarterly results suggest a deceleration in growth momentum. The fall in EPS by over 31% in the latest quarter is particularly concerning, as it reflects pressure on profitability and earnings quality. This negative financial trend has weighed heavily on investor sentiment and contributed to the downgrade in the investment rating.

Technical Analysis: Shift to Mildly Bearish Signals

The downgrade to a Sell rating was primarily driven by a change in Natco Pharma’s technical outlook, which shifted from mildly bullish to mildly bearish. Key technical indicators reveal a mixed but predominantly negative picture:

• MACD: Weekly readings are bearish, although monthly signals remain mildly bullish, indicating short-term weakness amid some longer-term support.
• RSI: Both weekly and monthly relative strength index readings show no clear signal, suggesting a lack of strong momentum in either direction.
• Bollinger Bands: Weekly indicators are mildly bearish, while monthly bands remain bullish, reflecting recent price volatility and potential downward pressure.
• Moving Averages: Daily moving averages have turned bearish, signalling a negative near-term trend.
• KST (Know Sure Thing): Weekly readings are bearish, with monthly indicators mildly bullish, again highlighting short-term weakness.
• Dow Theory: Weekly signals are mildly bullish, but monthly trends show no clear direction.
• On-Balance Volume (OBV): No significant trend is evident on weekly or monthly charts, indicating subdued trading volume support.

These technical factors collectively suggest that the stock is facing resistance and may continue to experience downward pressure in the near term. The current price of ₹917.30 is well below the 52-week high of ₹1,226.10, further underscoring the technical challenges.

Comparative Performance: Underperforming Benchmarks

Natco Pharma’s stock returns have lagged key market indices over multiple time horizons. The stock posted a negative 0.79% return over the past week, while the Sensex gained 2.17%. Over one month, Natco declined 1.64% against a 0.86% rise in the Sensex. Year-to-date, the stock has managed a modest 1.52% gain, outperforming the Sensex’s 7.97% loss, but this is overshadowed by longer-term underperformance.

In the last one year, Natco Pharma’s stock fell by 1.92%, underperforming the Sensex’s 3.20% decline. Over three years, the stock returned 10.00%, significantly below the Sensex’s 19.34%. The five-year return of -9.59% starkly contrasts with the Sensex’s strong 44.25% gain, highlighting the company’s struggles to keep pace with broader market growth.

Despite a positive 10-year return of 45.66%, this is still well behind the Sensex’s 182.99% gain, indicating that Natco Pharma has not been a consistent outperformer over the long term.

Conclusion: Downgrade Reflects Multiple Headwinds

Natco Pharma Ltd.’s downgrade from Hold to Sell is a reflection of its deteriorating financial performance, subdued valuation appeal, negative financial trends, and a shift to bearish technical indicators. While the company benefits from strong management efficiency, a net-debt-free balance sheet, and attractive valuation metrics, these positives are currently outweighed by declining sales, shrinking profits, and weakening price momentum.

Investors should exercise caution given the stock’s underperformance relative to market benchmarks and the mixed technical signals. The downgrade signals that Natco Pharma may face continued headwinds in the near term, and alternative investment opportunities may offer better risk-reward profiles.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →